<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811861</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-G000-307</org_study_id>
    <secondary_id>KEYNOTE-581</secondary_id>
    <secondary_id>2016-000916-14</secondary_id>
    <nct_id>NCT02811861</nct_id>
  </id_info>
  <brief_title>Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, Phase 3 study to compare the efficacy and&#xD;
      safety of lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) versus&#xD;
      sunitinib (Arm C) as first-line treatment in participants with advanced renal cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 13, 2016</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Actual">August 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) by Independent Imaging Review (IIR)</measure>
    <time_frame>From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)</time_frame>
    <description>PFS assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or death (whichever occurred first) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>ORR is defined as the proportion of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by IIR using RECIST 1.1. CR is defined as disappearance of all (targeted and non-target [NT]) lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (&lt;) 10mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>OS is defined as the time from the date of randomization to the date of death from any cause. Participants who were lost to follow-up and those who were alive at the data cutoff date were censored, either at the last date the participant was last known alive or at the data cutoff date, whichever occurred first. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With At Least One Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>TEAEs were defined as those adverse events (AEs) that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug.An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. A SAE was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Treatment Due to Toxicity</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure Due to Toxicity</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>Time to treatment failure due to toxicity is defined as time from the date of randomization to the date that a participant discontinued study treatment due to TEAEs. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL) Assessed by Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS) Scores</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>The FKSI-DRS consisted of 9 items that experts and participants had indicated are important targets for the treatment of advanced kidney cancer, and that clinical experts had indicated are primarily disease-related, as opposed to treatment-related. Symptoms assessed on the FKSI-DRS included lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or hematuria. Each item was scored on a 5-point Likert-type scale (0 = not at all; 4 = very much) where total score ranged from 0 (worst) to 36 (best), where higher scores correspond to better outcomes. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL Assessed by European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Score</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>EORTC QLQ-C30 is a questionnaire including 30 questions that rate the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. For the overall HRQoL and functioning scales, a higher score is correlated with better HRQoL, whereas a higher score represents worse HRQoL for symptom scales. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Score</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>EQ-5D-3L is a health profile questionnaire consisting of the EQ-5D descriptive system and the EuroQol visual analog scale (EQ-VAS). For the EQ-5D, participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) at 1 of 3 levels (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 (full health) to &lt;0 (worse health/dead). The EQ-VAS measures self-rated global health status using a vertically oriented VAS, where 100 represents the &quot;best imaginable health state&quot; and 0 represents the &quot;worst imaginable health state.&quot; Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS on Next-line of Therapy (PFS2)</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>PFS2 is defined as the time from randomization to disease progression as assessed by investigator on next-line treatment or death from any cause (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by Investigator Assessment</measure>
    <time_frame>Up to approximately 69 months</time_frame>
    <description>PFS by investigator assessment is defined as the time from the date of randomization to the date of first documentation of disease progression based on the investigator assessment per RECIST 1.1 or death (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model-predicted Clearance for Lenvatinib and Everolimus</measure>
    <time_frame>Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length=21 days)</time_frame>
    <description>Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib and Everolimus</measure>
    <time_frame>Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length = 21 days</time_frame>
    <description>Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1069</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Lenvatinib 18 mg plus everolimus 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenvatinib 20 mg plus pembrolizumab 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenvatinib 20 mg administered orally, once daily, plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunitinib 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenvatinib</intervention_name>
    <arm_group_label>Lenvatinib 18 mg plus everolimus 5 mg</arm_group_label>
    <arm_group_label>Lenvatinib 20 mg plus pembrolizumab 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <arm_group_label>Lenvatinib 18 mg plus everolimus 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <arm_group_label>Lenvatinib 20 mg plus pembrolizumab 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <arm_group_label>Sunitinib 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological confirmation of renal cell carcinoma (RCC) with a&#xD;
             clear-cell component&#xD;
&#xD;
          -  At least 1 measurable target lesion according to Response Evaluation in Solid Tumors&#xD;
             (RECIST) 1.1&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) of ≥70&#xD;
&#xD;
          -  Adequately controlled blood pressure (BP) with or without antihypertensive&#xD;
             medications, defined as BP ≤150/90 mmHg at Screening and no change in antihypertensive&#xD;
             medications within 1 week prior to Cycle 1/Day 1 (C1/D1)&#xD;
&#xD;
          -  Adequate organ function per blood work&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have received any systemic anticancer therapy for RCC, including&#xD;
             anti-vascular endothelial growth factor (VEGF) therapy, or any systemic&#xD;
             investigational anticancer agent&#xD;
&#xD;
          -  Participants with central nervous system (CNS) metastases are not eligible, unless&#xD;
             they have completed local therapy (eg, whole brain radiation therapy (WBRT), surgery&#xD;
             or radiosurgery) and have discontinued the use of corticosteroids for this indication&#xD;
             for at least 4 weeks before starting treatment in this study. Any signs (eg,&#xD;
             radiologic) or symptoms of CNS metastases must be stable for at least 4 weeks before&#xD;
             starting study treatment&#xD;
&#xD;
          -  Active malignancy (except for RCC, definitively treated basal or squamous cell&#xD;
             carcinoma of the skin, and carcinoma in-situ of the cervix or bladder) within the past&#xD;
             24 months. Participants with history of localized &amp; low risk prostate cancer are&#xD;
             allowed in the study if they were treated with curative intent and there is no&#xD;
             prostate specific antigen (PSA) recurrence within the past 5 years&#xD;
&#xD;
          -  Prior radiation therapy within 21 days prior to start of study treatment with the&#xD;
             exception of palliative radiotherapy to bone lesions, which is allowed if completed 2&#xD;
             weeks prior to study treatment start&#xD;
&#xD;
          -  Received a live vaccine within 30 days of planned start of study treatment&#xD;
&#xD;
          -  Participants with urine protein ≥1 gram/24 hour&#xD;
&#xD;
          -  Fasting total cholesterol &gt;300 milligram per deciliter (mg/dL) (or ˃7.75 millimole per&#xD;
             liter (mmol/L)) and/or fasting triglycerides level ˃2.5 x upper limit of normal (ULN).&#xD;
             Note: these participants can be included after initiation or adjustment of&#xD;
             lipid-lowering medication&#xD;
&#xD;
          -  Uncontrolled diabetes as defined by fasting glucose &gt;1.5 times the ULN. Note: these&#xD;
             participants can be included after initiation or adjustment of glucose-lowering&#xD;
             medication&#xD;
&#xD;
          -  Prolongation of corrected QT (QTc) interval to &gt;480 milliseconds (ms)&#xD;
&#xD;
          -  Bleeding or thrombotic disorders or participants at risk for severe hemorrhage. The&#xD;
             degree of tumor invasion/infiltration of major blood vessels should be considered&#xD;
             because of the potential risk of severe hemorrhage associated with tumor&#xD;
             shrinkage/necrosis following lenvatinib therapy&#xD;
&#xD;
          -  Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Significant cardiovascular impairment within 12 months of the first dose of study&#xD;
             drug: history of congestive heart failure greater than New York Heart Association&#xD;
             Class II, unstable angina, myocardial infarction, cerebrovascular accident, or cardiac&#xD;
             arrhythmia associated with hemodynamic instability. The following is also excluded:&#xD;
             left ventricular ejection fraction below the institutional normal range as determined&#xD;
             by multiple-gated acquisition scan or echocardiogram&#xD;
&#xD;
          -  Active infection (any infection requiring systemic treatment)&#xD;
&#xD;
          -  Participants known to be positive for Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          -  Known active Hepatitis B (eg, Hepatitis B surface antigen (HBsAg) reactive) or&#xD;
             Hepatitis C (eg, hepatitis C virus ribonucleic acid (HCV RNA) [qualitative] is&#xD;
             detected)&#xD;
&#xD;
          -  Known history of, or any evidence of, interstitial lung disease&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids, or current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Participants with a diagnosis of immunodeficiency or who are receiving chronic&#xD;
             systemic steroid therapy (doses exceeding 10 mg/day of prednisone equivalent) or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of study&#xD;
             treatment. Physiologic doses of corticosteroids (up to 10 mg/day of prednisone or&#xD;
             equivalent) may be used during the study&#xD;
&#xD;
          -  Active autoimmune disease (with the exception of psoriasis) that has required systemic&#xD;
             treatment in the past 2 years (ie, with use of disease modifying agents,&#xD;
             corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine,&#xD;
             insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary&#xD;
             insufficiency) is not considered a form of systemic treatment.&#xD;
&#xD;
          -  Known intolerance to any of the study drugs (or any of the excipients)&#xD;
&#xD;
          -  Participant has had an allogenic tissue/solid organ transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boca Raton Community Hospital</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists ( North Region)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology - Hematology Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network III, LLC</name>
      <address>
        <city>Tinley Park</city>
        <state>Illinois</state>
        <zip>60487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-Oneil Clinical Research Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology &amp; Hematology, PC</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital- MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GU Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosewell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broome Oncology</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital_ Cancer Care of Western North Carolina</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI - Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA - Paris</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USOR Texas Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Clinical Research Unit</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macquarie University Hospital</name>
      <address>
        <city>Macquarie park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Cancer Foundation</name>
      <address>
        <city>South Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH - Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O.L.V Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2260</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imeldaziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis - Campus Virga Jesse</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Domaine Universitaire</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GZA Ziekenhuizen - Campus Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Institute of Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute - University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de santé et de services sociaux Champlain-Charles-Le Moyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc, Neurologicka klinika</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice</name>
      <address>
        <city>Praha 4</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce</name>
      <address>
        <city>Praha 8</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <state>Maine Et Loire</state>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo - Centre Jean Bernard</name>
      <address>
        <city>Le Mans Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Regional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital la Petie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>cedex 13 75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulevard du Professeur Jacques Monod</name>
      <address>
        <city>Saint Herblain</city>
        <zip>4805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg - Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EISAI Trial site 4</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden Wuerttemberg</state>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EISAI Trial site 1</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EISAI Trial site 7</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EISAI Trial site 6</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EISAI Trial site 14</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EISAI Trial site 8</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EISAI Trial site 13</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EISAI Trial site 2</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EISAI Trial site 5</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Alexandra&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Patras Medical School</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Papageorgiou</name>
      <address>
        <city>Thessaloníki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interbalkan Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloníki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital,Wilton</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide and Meath Hospital Incorp The National Children's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Be'er Ya'aqov</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam MC</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapir Medical Center, Meir Hospital</name>
      <address>
        <city>Kfar-Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center-Beilinson Campus</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale- Ravenna</name>
      <address>
        <city>Faenza</city>
        <state>Ravenna</state>
        <zip>48018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Donato</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico SantOrsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Ricerca sul Cancro di Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.S.S Fondazione Maugeri</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria Degli Angeli</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Campus Bio-Medico di Roma</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #3</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #3</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #4</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #5</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #6</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center: Medical Oncology Department</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center: Urology Department</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine Division of Hematology/Oncology Cancer center 11F</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPWSZ w Szczecinie im. Marii Sklodowskiej-Curie</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin - Department of Oncology</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Moscow scientific research oncology institute n.a. P.A. Gertsen&quot; of MoH of RF</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin - Department of Urology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FBHI Privolzhskiy District Medical Centre FMBA of Russia</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Novosibirsk region &quot;Novosibirsk Regional Oncological Dispensary&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630108</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;National Medical Research Radiological Center&quot; of the MoH of the RF</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BHI of Omsk region &quot;Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO l'Hospitalet - Hospital Duran I Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Centre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital - Universitaetsspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth General Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West Of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <results_first_submitted>August 27, 2021</results_first_submitted>
  <results_first_submitted_qc>August 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2021</results_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cell Carcinoma (RCC)</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>First-line RCC</keyword>
  <keyword>Treatment-naive RCC</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Phase 3 RCC</keyword>
  <keyword>Phase 3 first-line RCC</keyword>
  <keyword>Phase 3 treatment-naive RCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02811861/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02811861/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 181 investigative sites in Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom of Great Britain and Northern Ireland, the United States of America, Australia, Czechia, Israel, Japan, Korea, Russian Federation, from 13 October 2016 to 28 August 2020 (date of data cutoff for the primary analysis of PFS and second interim analysis of Overall Survival).</recruitment_details>
      <pre_assignment_details>A total of 1417 participants were screened, of which, 1069 were randomized. Of the 1069 randomized, 1047 participants were treated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenvatinib 18 mg Plus Everolimus 5 mg</title>
          <description>Participants received lenvatinib 18 milligrams (mg) administered orally, once daily in each 21-day cycle, plus everolimus 5 mg administered orally, once daily in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.</description>
        </group>
        <group group_id="P2">
          <title>Lenvatinib 20 mg Plus Pembrolizumab 200 mg</title>
          <description>Participants received lenvatinib 20 mg administered orally, once daily in each 21-day cycle, plus pembrolizumab 200 mg administered intravenously, every 3 weeks in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.</description>
        </group>
        <group group_id="P3">
          <title>Sunitinib 50 mg</title>
          <description>Participants received sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="357"/>
                <participants group_id="P2" count="355"/>
                <participants group_id="P3" count="357"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="355"/>
                <participants group_id="P2" count="352"/>
                <participants group_id="P3" count="340"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="357"/>
                <participants group_id="P2" count="355"/>
                <participants group_id="P3" count="357"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Radiological Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="97"/>
                <participants group_id="P3" count="174"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Choice</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Ongoing at Cutoff Date</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis set (FAS) included all randomized participants regardless of the treatment actually received.</population>
      <group_list>
        <group group_id="B1">
          <title>Lenvatinib 18 mg Plus Everolimus 5 mg</title>
          <description>Participants received lenvatinib 18 milligrams (mg) administered orally, once daily in each 21-day cycle, plus everolimus 5 mg administered orally, once daily in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.</description>
        </group>
        <group group_id="B2">
          <title>Lenvatinib 20 mg Plus Pembrolizumab 200 mg</title>
          <description>Participants received lenvatinib 20 mg administered orally, once daily in each 21-day cycle, plus pembrolizumab 200 mg administered intravenously, every 3 weeks in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.</description>
        </group>
        <group group_id="B3">
          <title>Sunitinib 50 mg</title>
          <description>Participants received sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="357"/>
            <count group_id="B2" value="355"/>
            <count group_id="B3" value="357"/>
            <count group_id="B4" value="1069"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="10.86"/>
                    <measurement group_id="B2" value="62.3" spread="10.23"/>
                    <measurement group_id="B3" value="60.8" spread="9.96"/>
                    <measurement group_id="B4" value="61.7" spread="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="273"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="275"/>
                    <measurement group_id="B4" value="796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="339"/>
                    <measurement group_id="B3" value="334"/>
                    <measurement group_id="B4" value="1001"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="270"/>
                    <measurement group_id="B4" value="787"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) by Independent Imaging Review (IIR)</title>
        <description>PFS assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or death (whichever occurred first) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method.</description>
        <time_frame>From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)</time_frame>
        <population>The FAS included all randomized participants regardless of the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib 18 mg Plus Everolimus 5 mg</title>
            <description>Participants received lenvatinib 18 milligrams (mg) administered orally, once daily in each 21-day cycle, plus everolimus 5 mg administered orally, once daily in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Lenvatinib 20 mg Plus Pembrolizumab 200 mg</title>
            <description>Participants received lenvatinib 20 mg administered orally, once daily in each 21-day cycle, plus pembrolizumab 200 mg administered intravenously, every 3 weeks in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.</description>
          </group>
          <group group_id="O3">
            <title>Sunitinib 50 mg</title>
            <description>Participants received sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) by Independent Imaging Review (IIR)</title>
          <description>PFS assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or death (whichever occurred first) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method.</description>
          <population>The FAS included all randomized participants regardless of the treatment actually received.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="355"/>
                <count group_id="O3" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="11.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="23.9" lower_limit="20.8" upper_limit="27.7"/>
                    <measurement group_id="O3" value="9.2" lower_limit="6.0" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Stratified Log-rank Test</method>
            <method_desc>Hazard ratio is based on a Cox Proportional Hazards Model including treatment group as a factor.</method_desc>
            <param_type>Stratified Hazard Ratio</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Stratified Log-rank Test</method>
            <method_desc>Hazard ratio is based on a Cox Proportional Hazards Model including treatment group as a factor.</method_desc>
            <param_type>Stratified Hazard Ratio</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>ORR is defined as the proportion of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by IIR using RECIST 1.1. CR is defined as disappearance of all (targeted and non-target [NT]) lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (&lt;) 10mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as the time from the date of randomization to the date of death from any cause. Participants who were lost to follow-up and those who were alive at the data cutoff date were censored, either at the last date the participant was last known alive or at the data cutoff date, whichever occurred first. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With At Least One Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <description>TEAEs were defined as those adverse events (AEs) that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug.An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. A SAE was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Treatment Due to Toxicity</title>
        <description>Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure Due to Toxicity</title>
        <description>Time to treatment failure due to toxicity is defined as time from the date of randomization to the date that a participant discontinued study treatment due to TEAEs. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL) Assessed by Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS) Scores</title>
        <description>The FKSI-DRS consisted of 9 items that experts and participants had indicated are important targets for the treatment of advanced kidney cancer, and that clinical experts had indicated are primarily disease-related, as opposed to treatment-related. Symptoms assessed on the FKSI-DRS included lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or hematuria. Each item was scored on a 5-point Likert-type scale (0 = not at all; 4 = very much) where total score ranged from 0 (worst) to 36 (best), where higher scores correspond to better outcomes. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRQoL Assessed by European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Score</title>
        <description>EORTC QLQ-C30 is a questionnaire including 30 questions that rate the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. For the overall HRQoL and functioning scales, a higher score is correlated with better HRQoL, whereas a higher score represents worse HRQoL for symptom scales. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRQoL Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Score</title>
        <description>EQ-5D-3L is a health profile questionnaire consisting of the EQ-5D descriptive system and the EuroQol visual analog scale (EQ-VAS). For the EQ-5D, participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) at 1 of 3 levels (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 (full health) to &lt;0 (worse health/dead). The EQ-VAS measures self-rated global health status using a vertically oriented VAS, where 100 represents the &quot;best imaginable health state&quot; and 0 represents the &quot;worst imaginable health state.&quot; Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS on Next-line of Therapy (PFS2)</title>
        <description>PFS2 is defined as the time from randomization to disease progression as assessed by investigator on next-line treatment or death from any cause (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS by Investigator Assessment</title>
        <description>PFS by investigator assessment is defined as the time from the date of randomization to the date of first documentation of disease progression based on the investigator assessment per RECIST 1.1 or death (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Up to approximately 69 months</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model-predicted Clearance for Lenvatinib and Everolimus</title>
        <description>Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length=21 days)</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib and Everolimus</title>
        <description>Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).</description>
        <time_frame>Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length = 21 days</time_frame>
        <posting_date>07/2023</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug (Baseline) up to 30 days after last dose of study drug or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)</time_frame>
      <desc>Safety analysis set included all participants who received at least 1 dose of any study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lenvatinib 18 mg Plus Everolimus 5 mg</title>
          <description>Participants received lenvatinib 18 milligrams (mg) administered orally, once daily in each 21-day cycle, plus everolimus 5 mg administered orally, once daily in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.</description>
        </group>
        <group group_id="E2">
          <title>Lenvatinib 20 mg Plus Pembrolizumab 200 mg</title>
          <description>Participants received lenvatinib 20 mg administered orally, once daily in each 21-day cycle, plus pembrolizumab 200 mg administered intravenously, every 3 weeks in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.</description>
        </group>
        <group group_id="E3">
          <title>Sunitinib 50 mg</title>
          <description>Participants received sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood loss anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Eosinophilia myalgia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Secondary hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Steroid withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Retinal vascular occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vogt-Koyanagi-Harada disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Eosinophilic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastroduodenal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Immune-mediated enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Immune-mediated pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Inadequate analgesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Immune-mediated hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Septic arthritis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Radiation injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Radiation proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bone lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>External ear neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastases to chest wall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastases to skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pericardial effusion malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cytotoxic oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Myasthenic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Noninfective encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Paralysis recurrent laryngeal nerve</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device deposit issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis migrans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="353" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="351" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="332" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="166" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="131" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="127" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Yellow skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Medical Information</name_or_title>
      <organization>Eisai, Inc.</organization>
      <phone>+1-888-274-2378</phone>
      <email>esi_oncmedinfo@eisai.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

